Page 73 - New epidemiological and PSMA-expression based paradigms in salivary gland tumors

Malignant transformation of pleomorphic adenoma: Proof of principle
References
1 Valstar M, Andreasen S, Bhairosing P, et al. Natural history of recurrent pleomorphic adenoma: implications on management. Head Neck 2020; 42: 2058-2066
2 de Ridder M, Balm AJM, Smeele LE, et al. An epidemiological evaluation of salivary gland cancer in the Netherlands (1989-2010). Cancer Epidemiol 2015; 39: 14-20
3 Röijer E, Nordkvist A, Ström A, et al. Translocation, deletion/amplification, and expression of HMGIC and MDM2 in a carcinoma ex pleomorphic adenoma. Am J Pathol 2002; 160: 433-440
4 Lewis J, Olsen K, Sebo T. Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. Hum Pathol 2001; 36: 596-604
5 Ihrler S, Guntinas-Lichius O, Agaimy A, et al. Histological, immunohistological and molecular characteristics of intraductal precursor of carcinoma ex pleomorphic adenoma support a multistep carcinogenic process. Virchows Arch 2017; 470: 601-609
6 Stenman G. Fusion oncogenes in salivary gland tumors: molecular and clinical consequences. Head Neck Pathol 2013; 7: S12-19
7 Bell D, Myers J, Rao P, et al. t(3;8) as the sole chromosomal abnormality in a myoepithelial carcinoma ex pleomorphic adenoma: a putative progression event. Head Neck 2012; 35: E181-3
8 Deguchi H, Hamano H, Hayashi Y. c-myc, ras p21 and p53 expression in pleomorphic adenoma and its malignant form of the human salivary glands. Acta Pathol Jpn 1993; 43: 413-422
9 Di Palma S. Carcinoma Ex Pleomorphic Adenoma, with Particular Emphasis on Early Lesions. Head Neck Pathol 2013; 7: 68-76
10 Bullerdiek J, Raabe G, Bartnitzke S, et al. Structural rearrangements of chromosome Nr 8 involving 8q12-a primary event in pleomorphic ademona of the parotid gland. Genetica 1987; 72: 85-92
11 Kas K, Voz M, Röijer E, et al. Promoter swapping between the genes for a novel zinc finger protein and beta-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) translocations. Nat Genet 1997; 15: 170- 174
12 Voz ML, Astrom AK, Kas K, et al. The recurrent translocation t(5;8)(p13;q12) in pleomorphic adenomas results in upregulation of PLAG1 gene expression under control of the LIFR promoter. Oncogene 1998; 16: 1409-1416
13 Grünewald I, Vollbrecht C, Meinrath J, et al. Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity. Oncotarget 2015; 20: 18224-18237
14 Persson F, Andrén Y, Winnes M, et al. High-resolution genomic profiling of adenomas and carcinomas of the salivary glands reveals amplification, rearrangement, and fusion of HMGA2. Genes Chromosom Cancer 2009; 48: 69-82
15 Gomes C, Diniz M, Orsine L, et al. Assessment of TP53 mutations in benign and malignant salivary gland neoplasms. PLoS One 2012; 7: e41261
16 Nordkvist A, Röijer E, Bang G, et al. Expression and mutation patterns of p53 in benign and malignant salivary gland tumors. Int J Oncol 2000; 16: 477-483
17 Ihrler S, Weiler C, Hirschmann A, et al. Intraductal carcinoma is the precursor of carcinoma ex pleomorphic adenoma and is often associated with dysfunctional p53. Histopathology 2007; 51: 362- 371
18 Righi P, Li Y, Deutsch M, et al. The role of the p53 gene in the malignant transformation of pleomorphic adenomas of the parotid gland. Anticancer Res 1994; 14: 2253-2257
19 Chiosea S, Thompson L, Weinreb I, et al. Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations. Cancer 2016; 122: 3136-3144
20 El-Naggar A, Chan J, Takata T, et al. WHO Classification of Tumours. Pathology and Genetics of Head and Neck Tumours. 4th ed. Lyon: IARC Press; 2017.
21 Antony J, Gopalan V, Smith R a., et al. Carcinoma ex Pleomorphic Adenoma: A Comprehensive Review of Clinical, Pathological and Molecular Data. Head Neck Pathol 2012; 6: 1-9
22 Dubbink H, Atmodimedjo P, van Marion R, et al. Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing: 1p/19q Co-Deletion Analysis of Gliomas. J Mol Diagn 2016; 18: 775- 786
4
71